Tevogen, Inc. (TVGN)
6.67
-0.31
(-4.44%)
USD |
NASDAQ |
Oct 05, 16:00
6.67
0.00 (0.00%)
After-Hours: 20:00
Tevogen Net Income (Quarterly) : -5.762M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.762M |
| March 31, 2026 | -5.446M |
| December 31, 2025 | -4.678M |
| September 30, 2025 | -5.727M |
| June 30, 2025 | -5.504M |
| March 31, 2025 | -10.37M |
| December 31, 2024 | -9.250M |
| September 30, 2024 | -5.909M |
| June 30, 2024 | -6.050M |
| March 31, 2024 | 10.51M |
| December 31, 2023 | -3.632M |
| Date | Value |
|---|---|
| September 30, 2023 | -3.905M |
| June 30, 2023 | -22.18M |
| March 31, 2023 | -30.76M |
| December 31, 2022 | 2.614M |
| September 30, 2022 | 1.613M |
| June 30, 2022 | 0.207M |
| March 31, 2022 | -0.026M |
| December 31, 2021 | -0.0173M |
| September 30, 2021 | -0.0001M |
| June 30, 2021 | -0.0113M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.762M |
| EPS Diluted (Quarterly) | -1.525 |
| Enterprise Value | 46.86M |
| Earnings Yield | -87.42% |
| Normalized Earnings Yield | -87.68 |